Biotech Frontiers

Life-science and biotech investing is our focus in Biotech Frontiers… Some startups follow a clear, smooth path to success. Others skyrocket, then quickly fall back to Earth. But, generally speaking, as a sector, biotech stocks perform differently than tech stocks, “forever stocks,” and certainly the blue chips… Biotech veteran Erez Kalir heads up this advisory that publishes on the first Thursday of each month, with regular unscheduled updates as they are needed.

Issues & Updates


  • Update: SharpLink Gaming (SBET) and GDS Holdings (GDS)
    This coming January will mark two years since we launched Tech Frontiers and its predecessor, Biotech Frontiers. During that time, we’ve compiled an extraordinary track record: Eight of our recommendations have appreciated over 100% and many others have appreciated at least 50%. In the meantime, in our biotech portfolio, we encountered only two meaningful losers
    Read More
  • China’s AI Landlord
    China’s artificial intelligence sector is not in a market bubble. In fact, the company Erez Kalir recommends this month trades at a significantly lower valuation than its U.S. peers and is poised to soar going forward.
    Read More
  • A Piggybank For Ethereum
    If you’ve missed out on Bitcoin’s and Ethereum’s meteoric rise, this month’s issue of Tech Frontiers is for you. If you’ve ridden these meteors, congratulations – this issue will offer you a thoughtful way to diversify your gains and stay onboard.
    Read More
  • Sell Alert: Half Position Of Prime Medicine
    Shares of the Tech Frontiers July recommendation, Prime Medicine (Nasdaq: PRME), are trading at around $6.37 today, a gain of over 100% from our entry price of $3.07 three months ago. As a result, we recommend selling half your position. Prime is making terrific progress advancing its gene-editing platform and we have many reasons for
    Read More

See All Issues & Updates

Special Reports

America’s Last Election

See All Special Reports